#101: Cochrane salt/BP message blasted; US on "triple-therapy" for AF patients with stents; RE-MEDY on dabigatran vs warfarin for VTE; benefits of exercise on CHD risk; statins and stroke of unknown cause

This feature requires the newest version of Flash. You can download it here.

For the week ending August 5, 2011 we discuss the following top cardiology news from heartwire :

• Cochrane salt/blood-pressure message blasted in the Lancet

• US responds to ESC's "triple-therapy" advice for AF patients with stents

• RE-MEDY: Dabigatran noninferior to warfarin for extended treatment of VTE

• First study to quantify benefits of exercise on CHD risk

• Statins reduce recurrence after stroke of unknown cause

And also, in brief:

• AFNET and EHRA propose physiology-based atrial-fibrillation classification scheme

• FDA's 510(k) system broken and should be scrapped, IoM concludes

• Congress passes debt deal; could reduce Medicare payments

Join us for a comprehensive review of this week's most important cardiology news.

Cite this: #101: Cochrane salt/BP message blasted; US on "triple-therapy" for AF patients with stents; RE-MEDY on dabigatran vs warfarin for VTE; benefits of exercise on CHD risk; statins and stroke of unknown cause - Medscape - Aug 05, 2011.